Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 10/20 | 0.47 |
| ▸ | CA2 | P00918 | 10/20 | 0.47 |
| ▸ | CA9 | Q16790 | 10/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 10/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL983323 | 0.93 | CA1 (0.47) | DRD1CA1CA2CA9CA14 | |
| SCHEMBL985916 | 0.90 | CA1 (0.47) | DRD1CA1CA2CA9CA14 | |
| SCHEMBL986105 | 0.88 | DRD1 (0.52) | DRD1CA1CA2CA9CA14 | |
| SCHEMBL986126 | 0.85 | CA1 (0.55) | DRD1CA1CA2CA9CA14 | |
| SCHEMBL985863 | 0.85 | CA1 (0.55) | DRD1CA1CA2CA9CA14 | |
| SCHEMBL985919 | 0.85 | PDE4D (0.45) | CA1CA2CA9CA14CA7 | |
| SCHEMBL4673775 | 0.83 | DRD1 (0.52) | DRD1CA1CA2CA9CA14 | |
| SCHEMBL988054 | 0.83 | CA1 (0.50) | DRD1CA1CA2CA9CA14 | |
| SCHEMBL985355 | 0.81 | TSHR (0.58) | DRD1CA1CA2CA9CA14 | |
| SCHEMBL24724677 | 0.80 | MEN1 (0.56) | CA1CA2CA9CA14CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875631-B2 | e.g.1-(3,5-dichlorophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline; to prevent and/or treat cancer and other abnormal cell growth, and metabolic as well as blood vessel proliferate disorders, in which uncontrolled expression of insulin-like growth factor-1 receptor is observed | ANALYTECON S.A. (CH) | 2011-01-25 | — | — | US | claimed |
| EP-1732898-B1 | TETRAHYDROISOQUINOLINE- AND TETRAHYDROBENZAZEPINE DERIVATIVES AS IGF-1R INHIBITORS | ANALYTECON SA (CH) | 2008-01-23 | — | — | EP | claimed |
| US-20070129399-A1 | Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors | ANALYTECON S.A. (CH) | 2007-06-07 | — | — | US | claimed |
| EP-1732898-B1 | TETRAHYDROISOQUINOLINE- AND TETRAHYDROBENZAZEPINE DERIVATIVES AS IGF-1R INHIBITORS | ANALYTECON SA (CH) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129399-A1 | Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors | IGF1R, INSR, GPR119 | DRD1 502/4885CA1 3524/4885CA2 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.